Global Amifostine market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 50 million in 2020. Over the next five years the Amifostine market will register a 2.3% CAGR in terms of revenue, the global market size will reach US$ 55 million by 2026.
Amifostine Market Overview
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.
Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.
The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.
Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.
Recent Development:
Luye Pharma’s Investigational Analgesic LY03014 Reaches Endpoints in a Phase I Clinical Trial in China
Shanghai, May 10, 2022 - Luye Pharma Group announced today that its investigational drug LY03014, designated as a “Class 1 New Drug” in China, has reached the endpoints in a Phase I clinical trial. Developed on Luye Pharma’s New Molecular Entity platform as an innovative analgesic, LY03014 is a small molecule Gi protein biased at mu-opioid receptor agonist for the treatment of moderate to severe acute postoperative pain and breakthrough cancer pain.
The Phase I clinical trial completed in China was a randomized, double-blind, placebo-controlled, and dose escalation clinical study in healthy subjects, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single intravenous infusion of LY03014. The results showed that a single intravenous infusion of L
What are the major Applications, Types, and Regions of the Amifostine Market?
Amifostine Market is segmented based on the type, applications, companies, and regions.
By Type, Amifostine Market has been segmented into
400mg/Dose
500mg/Dose
Others
The end user’s industry application on Amifostine Market is,
Head and Neck Cancer Adjuvant Therapy
Others
Regional Analysis:
The report offers in-depth assessment of the growth and other aspects of the Amifostine Market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.
Amifostine Market highlights the potential growth opportunities in upcoming years, while reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape and other key aspects in the global market. The Global Amifostine Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. This Research Study compares the markets of Pre COVID-19 and Post COVID-19 with the impact of COVID-19 on the regional economy.
What is our Amifostine Market report scope?
The report incorporates in-depth assessment of the competitive landscape, product market sizing, product benchmarking, market trends, product developments, financial analysis, strategic analysis and so on to gauge the impact forces and potential opportunities of the market. Apart from this the report also includes a study of major developments in the market such as product launches, agreements, acquisitions, collaborations, mergers and so on to comprehend the prevailing market dynamics at present and its impact during the forecast period 2021-2026. The report presents the analysis of Amifostine Market for the historical period of 2017-2021 and the forecast period of 2021-2026.
The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Technological Innovations, and Role of Manufacturers during COVID19 Pandemic. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analyzed in the report.
Reports Attributes
|
Report Details
|
Forecast Period 2022 to 2027 CAGR
|
CAGR of 2.3% during the review period (2022 to 2027).
|
By Type
|
- 400mg/Dose
- 500mg/Dose
- Other
|
By Application
|
- Industrial
- Head and Neck Cancer Adjuvant Therapy
- Others
|
By Companies
|
CLINIGEN GROUP PLC (Aquis AQSE :CLIN-GB.AQ), Sun Pharmaceutical Industries Limited (NSE :SUNPHARMA.NS), Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma
|
Regions Covered
|
• North America
• Europe
• Asia-Pacific
• Rest of the World
|
Countries Covered
|
• US
• Canada
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• Middle East & Africa
• Latin America
|
Base Year
|
2022
|
Historical Year
|
2017 to 2021
|
Forecast Year
|
2022 to 2027
|
Number of Pages
|
99
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Key Takeaways from this Amifostine Report
- Evaluate Amifostine market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.
- Understand the different dynamics influencing the market - key driving factors, challenges and hidden opportunities.
- Get in-depth insights on your competitor performance - market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
- Analyze the sales and distribution channels across key geographies to improve top-line revenues.
- Understand the industry supply chain with a deep dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
- Get a quick outlook on the Amifostine market entropy - M&A's, deals, partnerships, and product launches of all key players for the past 4 years.
- Evaluate the supply-demand gaps, import-export statistics, and regulatory landscape for more than the top 20 countries globally for the market.
All our reports are customizable to your company's needs to a certain extent, we do provide 5 free consulting hours along with the purchase of each report, and this will allow you to request any additional data to customize the report to your needs.
Frequently Asked Questions
What is the study period of this market?
The Amifostine Market is studied from 2017 - 2027.
Who are the key players in Amifostine Market?
CLINIGEN GROUP PLC (Aquis AQSE :CLIN-GB.AQ), Sun Pharmaceutical Industries Limited (NSE :SUNPHARMA.NS), Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma and others.
What are the significant types of Amifostine Market?
400mg/Dose, 500mg/Dose, Other.
What are the major end-use applications of the Amifostine Market?
Head and Neck Cancer Adjuvant Therapy, Others, Other.
What segments are covered in the Amifostine Market report?
The Global Amifostine Market is Segmented on the basics of Product, Application, and Geography.
How can I get a sample report/company profile for the Amifostine Market?
The sample report for the Amifostine Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
